search
Back to results

Genomic Study of Cutis Tricolor (Cutis Tricolor)

Primary Purpose

Pigmentary; Dermatosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Blood sample
Cutaneous biopsy
High troughput sequencing of human's exome
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pigmentary; Dermatosis

Eligibility Criteria

4 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents) Age : from 4 to 60 years Exclusion Criteria: Refusal to sign the informed consent Patient who doesn't have a social security scheme or beneficiary of such a scheme Pregnant or breastfeeding women Patient whith a legal protection measure (guardianship, curatorship) Patient under legal protection

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Cutis Tricolor patient included in trio or duo

    Arm Description

    Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)

    Outcomes

    Primary Outcome Measures

    Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing

    Secondary Outcome Measures

    Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified

    Full Information

    First Posted
    May 19, 2023
    Last Updated
    October 3, 2023
    Sponsor
    University Hospital, Montpellier
    Collaborators
    IntegraGen SA
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06073171
    Brief Title
    Genomic Study of Cutis Tricolor
    Acronym
    Cutis Tricolor
    Official Title
    Genomic Study of Cutis Tricolor
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    October 2024 (Anticipated)
    Study Completion Date
    March 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Montpellier
    Collaborators
    IntegraGen SA

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    It's a study on Syndromic or Isolated Cutis Tricolor and had as main goal to identify the associated gene to the disease thanks to genetic analysis on minors patients and their parents reach by cutis Tricolor or not.
    Detailed Description
    Cutis Tricolor (CT) is a rare cutaneous anomaly defined by pigmentary disorders associating large hyper- and hypopigmented macules of immediate proximity, selectively affecting the trunk. CT can be isolated, sporadic or integrated as a complex syndromic form such as Ruggieri-Happle syndrome (RHS) or various forms of pigmentovascular phacomatosis. A recent analysis of one case of RHS followed by CHU of Montpellier by whole exome sequencing allows the identification of a frameshift pathogen variant (heterozygous state) of a candidate gene. The main objective is to confirm the association of the candidate gene with syndromic CT (SCT, Ruggierri-Happle syndrome) and non syndromic CT, from a genetic molecular blood and biopsy analysis of patients reach by CT and their parents presenting the disease or not. Furthermore, other objectives are to identify others associated candidates genes and to know better cutaneous pigmentary troubles factors, neurologics and eye abnormalities by identifying the differents cellulars pathways particularly the inflammatory pathway in the pathology of SCT. First of all, it will have a pre-inclusion visit where Dr WILLEMS. M (Clinical Genetic Department - CHU Montpellier, France) and Pr BESSIS. D (Dermatology Department - CHU Montpellier, France) will explain the study's progress. Then, during the inclusion visit, families will sign inform consent for inclusion in the study. The same day, datas will be collected on demographic, clinical datas, including (i) a description of cutaneous, morphologic and extra-cutaneous anomalies and (ii) a cutaneous biopsy and (iii) a blood test will be done. The genetics exams results will be return to patients during an usual follow-up visit, 12 months after their inclusion in the study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pigmentary; Dermatosis

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Cutis Tricolor patient included in trio or duo
    Arm Type
    Other
    Arm Description
    Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)
    Intervention Type
    Biological
    Intervention Name(s)
    Blood sample
    Intervention Description
    7.5 mL will be sampled on EDTA tube for each patient
    Intervention Type
    Biological
    Intervention Name(s)
    Cutaneous biopsy
    Intervention Description
    4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
    Intervention Type
    Genetic
    Intervention Name(s)
    High troughput sequencing of human's exome
    Intervention Description
    Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
    Primary Outcome Measure Information:
    Title
    Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    4 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents) Age : from 4 to 60 years Exclusion Criteria: Refusal to sign the informed consent Patient who doesn't have a social security scheme or beneficiary of such a scheme Pregnant or breastfeeding women Patient whith a legal protection measure (guardianship, curatorship) Patient under legal protection
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Didier BESSIS, Prof.
    Phone
    04 67 33 69 06
    Email
    d-bessis@chu-montpellier.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Marjolaine WILLEMS, Dr
    Phone
    04 67 33 65 64
    Email
    m-willems@chu-montpellier.fr

    12. IPD Sharing Statement

    Learn more about this trial

    Genomic Study of Cutis Tricolor

    We'll reach out to this number within 24 hrs